Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 19/20 | 0.63 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PTPRF | P10586 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500493 | 1.00 | PTPRB (0.63) | PTPRBPTPN11KDM4EPOLBMAPT | |
| SCHEMBL8523603 | 0.92 | PTPRB (0.52) | PTPRBKDM4EPOLBMAPT | |
| SCHEMBL8769454 | 0.89 | PTPRB (0.64) | PTPRBPTPN11 | |
| SCHEMBL12944598 | 0.87 | PTPRB (0.62) | PTPRBPTPN11 | |
| SCHEMBL679649 | 0.85 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL29794256 | 0.85 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL686535 | 0.85 | MAPT (0.47) | PTPRBKDM4EPOLBMAPT | |
| SCHEMBL468143 | 0.85 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL467932 | 0.84 | PTPRB (0.62) | PTPRBPTPN11PTPRFPTPN2PTPN1 | |
| SCHEMBL29794268 | 0.84 | PTPRB (0.62) | PTPRBPTPN11PTPRFPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | claimed |
| EP-2038265-B1 | Human protein-tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8106078-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | WARNER CHILCOTT COMPANY, LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885PTPN11 88/4885KDM4E 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.